Cancer research test targets tumor-suppressor protein, 1/14
January 2014—Spring Bioscience has added the Anti-PTEN (SP218) rabbit monoclonal immunohistochemistry antibody to its portfolio of antibodies for cancer research.
Webinars and Sponsored Roundtables — Register Now
Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.
Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Marketplace Directory
ICE COLD-PCR analysis presented, 1/14
January 2014—Transgenomic in October announced the results of a research collaboration with MD Anderson Cancer Center employing the company’s ICE COLD-PCR platform. This interim analysis demonstrates that in a high percentage of patients with advanced cancers, the same genetic mutations were detected in cell-free DNA present in the blood as were originally found in primary tumors. In a subset of patients followed over time, detection of mutations in cfDNA correlated with response to therapy or disease progression.
Freezerworks Unlimited upgrade, 1/14
January 2014—Dataworks Development released an upgrade, version 6.0, to its Freezerworks Unlimited freezer inventory and sample management software program. Expanded configurability in version 6.0 is most notable with improvements and greater capabilities in screen design and layout, as well as in adapting the shipping processes to the workflow of the lab, biobank, and repository. The report writer has been redesigned to offer a more user-friendly interface for developing and printing reports, while adding flexibility for subtotaling and inventory counts. Users can also bar code any data field on a report for quick and accurate accessing of sample records and data.
MPLN acquires MiSeqDx, 1/14
January 2014—Molecular Pathology Laboratory Network has acquired the Illumina MiSeqDx and will use the system to expand testing across all of its clinical laboratories, including its clinical trials group Geneuity Clinical Research Services. MPLN is a molecular reference laboratory specializing in oncology, women’s health, and clinical research services.
Epigenomics’ biomarker shows promising results in clinical study, 1/14
January 2014—Epigenomics announced the results from a clinical study that showed methylated SHOX2 to be a sensitive and specific biomarker for therapy monitoring and early detection of tumor response in lung cancer patients.
CLSI EP26 guideline, 1/14
January 2014—The Clinical and Laboratory Standards Institute has published a new document, “EP26-A–User Evaluation of Between-Reagent Lot Variation; Approved Guideline.”
Miraca acquires PLUS, 1/14
January 2014—Miraca Life Sciences (MLS) has acquired PLUS Diagnostics from Water Street Healthcare Partners. MLS provides diagnostic services in dermatology, gastroenterology, hematology, and urology.
Favorable results for CINtec PLUS cytology test, 1/14
January 2014—Ventana Medical Systems announced the positive findings of the Primary ASC-US LSIL Marker Study (PALMS) that have been published in The Journal of the National Cancer Institute (Ikenberg H, et al. 2013;105[20]:1550–1557).
Genetic profile for patients with DLBCL, 1/14
January 2014—Diagnovus announced an addition to its Engauge cancer assay portfolio with the launch of the Engauge-cancer DLBCL Gene Panel, a genomic profile to aid physicians in tailoring treatment specifically for patients with diffuse large B-cell lymphoma.
nCounter Dx Analysis, 1/14
January 2014—NanoString Technologies launched its nCounter Dx Analysis System for high-complexity, CLIA-certified laboratories. The nCounter Dx Analysis System is the only platform 510(k) cleared by the FDA to run the Prosigna Prognostic Breast Cancer Gene Signature Assay.